Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Recipient : Proteros
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership brings together Proteros’ discovery capabilities which are tailored to unlock even the most technically challenging drug targets with Adrestia’s expertise in target biology with a novel synthetic rescue drug development platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Recipient : Proteros
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $1,150.0 million
Deal Type : Collaboration
Details : The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $1,150.0 million
Deal Type : Collaboration
Reset All
